AGO4

Across TCGA pan-cancer cohorts, AGO4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AGO4 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AGO4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGO4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where AGO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	26	view →
PDAC	OS	Tertile	All	0.723	0.320	.010	5	view →
LSCC	OS	Median	II,III,IV	0.860	0.695	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AGO4–LUAD (OS)

Open the LUAD breakdown →